Sign in
CompletedPhase 3

Olorofim Aspergillus Infection Study

Key facts

Who runs it
F2G Ltd
Where
Ann Arbor, Augusta, Baltimore, Bethesda, Birmingham, Boston, Chapel Hill, Chicago, Duarte, Durham, Gainesville, Houston, Kansas City, Las Vegas, Minneapolis, New Brunswick, New York, Oklahoma City, Pittsburgh, Rochester, Sacramento, San Francisco, Seattle, and St Louis, United StatesSee the 24 sitesAlso in 20 other countries, 119 sites
Trial code
Status
Completed
Phase
Phase 3
People taking part
225 people enrolled
Started
29 Apr 2022
Ended
19 Mar 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Olorofim
  • AmBisome®
Record updated
8 October 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Male and female patients ages over 18 years and weighing more than 30 kg
  • Patients with proven IA at any site or probable LRTD IA per EORTC/MSG 2019 criteria as adapted for this study and where the duration of specific therapy for this episode of IA has been ≤ 28 days. For purposes of this inclusion, the duration of specific therapy includes any mould-active therapy given for this episode of IA whether subsequently judged potentially effective or not
  • Patients requiring therapy with an antifungal agent other than a mould-active azole, and who have had ≤ 96 hours of potentially effective prior therapy. Potentially effective prior therapy includes any agent to which the infecting strain of Aspergillus is likely to be susceptible. There are no exclusions or limitations on such agents (eg, AmBisome® is permitted) other than their duration
  • AmBisome® is an appropriate therapy for the patient

Who cannot take part

  • Patients with a known active second fungal infection of any type, other than candidiasis that can be treated with fluconazole
  • Human immunodeficiency virus (HIV) infection but not currently receiving antiretroviral therapy
  • Known history of allergy, hypersensitivity, or any serious reaction to any component of the study drug
  • Patients with only chronic aspergillosis, aspergilloma, or allergic bronchopulmonary aspergillosis
  • Microbiological findings (eg, bacteriological, virological) or other potential conditions that are temporally related and suggest a different aetiology for the clinical features
  • Patients with a baseline prolongation of QT using Fridericia's Correction Formula (QTcF) ≥ 500 msec, or at high risk for QT/QTc prolongation
  • Women who are pregnant or breastfeeding
  • Suspected mucormycosis (zygomycosis)
  • The requirement for ongoing use of echinocandin as Candida prophylaxis
  • Evidence of hepatic dysfunction

Where in United States

Also in 20 other countries, 119 sites

  • University of MichiganAnn Arbor, United States
  • Augusta UniversityAugusta, United States
  • The Johns Hopkins HospitalBaltimore, United States
  • NIH Clinical Center ,NIAID,NIHBethesda, United States
  • University of Alabama at BirminghamBirmingham, United States
  • Massachusetts General HospitalBoston, United States
  • University of North Carolina at Chapel HillChapel Hill, United States
  • University of Chicago Medical CenterChicago, United States
  • City of Hope National Medical CenterDuarte, United States
  • Duke Department of Medicine Infectious Diseases DivisionDurham, United States
  • University of FloridaGainesville, United States
  • Houston MethodistHouston, United States
  • University of Kansas Medical CenterKansas City, United States
  • Clairvoyant Research Group, LLCLas Vegas, United States
  • University of MinnesotaMinneapolis, United States
  • Rutgers-RWJMSNew Brunswick, United States
  • Weill Cornell Medicine NY Presbyterian HospitalNew York, United States
  • OU Health OU Medical CenterOklahoma City, United States
  • University of Pittsburgh Medical Center Health SystemPittsburgh, United States
  • Mayo Clinic - RochesterRochester, United States
  • University of California Davis Health SystemSacramento, United States
  • UCSF Helen Diller Medical Center at Parnassus HeightsSan Francisco, United States
  • Fred Hutchinson Cancer CenterSeattle, United States
  • Washington University School of MedicineSt Louis, United States

About the trial

What the trial wants to find out

The purpose of this study is to compare treatment with olorofim versus treatment with AmBisome® followed by standard of care (SOC) in patients with IFD caused by proven IA or probable lower respiratory tract disease Aspergillus species (invasive aspergillosis, IA).

The 2 groups in the trial

  • OlorofimExisting treatment, for comparison

    Olorofim versus AmBisome followed by Standard of Care (SOC)

  • AmBisomeExisting treatment, for comparison

    Olorofim versus AmBisome followed by Standard of Care (SOC)

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Phase III, Adjudicator-blinded, Randomised Study to Evaluate Efficacy and Safety of Treatment With Olorofim Versus Treatment With AmBisome® Followed by Standard of Care in Patients With Invasive Fungal Disease Caused by Aspergillus Species
Publications
Record updated
8 October 2026